Superworth

PTC Therapeutics EPS PTCT

Diluted earnings per share by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
−$0.55
Latest quarter, Q2 FY26
$0.92
Fiscal year 2025
$7.77

PTC Therapeutics' earnings per share was −$0.55 over the twelve months to Jun 30, 2026, down 108% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.92.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$7.77n/a
FY2024−$4.73n/a
FY2023−$8.36n/a
FY2022−$7.79n/a
FY2021−$7.43n/a
FY2020−$6.70n/a
FY2019−$4.47n/a
FY2018−$2.69n/a
FY2017−$2.08n/a
FY2016−$4.17n/a
FY2015−$5.06n/a
FY2014−$3.04n/a
FY2013−$6533.75n/a
FY2012n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.92n/a−$0.55
Q1 FY26−$0.03−100%−$2.30
Q4 FY25−$1.64n/a$7.77
Q3 FY25$0.20n/a$8.56
Q2 FY25−$0.83n/a$6.97
Q1 FY25$10.04n/a$6.51
Q4 FY24−$0.85n/a−$4.73
Q3 FY24−$1.39n/a−$5.94
Q2 FY24−$1.29n/a−$6.31
Q1 FY24−$1.20n/a−$7.68
Q4 FY23−$2.06n/a−$8.36
Q3 FY23−$1.76n/a−$8.65

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
PTCTPTC Therapeutics−$0.55−108% a year
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
INDVIndivior Pharmaceuticals$2.78+227% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
ARQTArcutis Biotherapeutics$0.22
LQDALiquidia$1.39
OGNOrganon$0.77−71% a year
ALKSAlkermes plc.$0.38−82% a year
TGTXTG Therapeutics$2.74+641% a year
PTGXProtagonist Therapeutics$1.03+47% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.